pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX
Travere Therapeutics
Travere Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
- Founded
- 2020
- Employees
- 506
- Programs
- 13
- Drugs
- 9
- Patents
- 1
Travere Therapeutics projects
3 ClinicalTrials.gov programs sponsored by Travere Therapeutics.
Travere Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
RE-021 (Sparsentan)
Travere Therapeutics
Focal Segmental Glomerulosclerosis
1 trial -
RTRX-RE021-201
Travere Therapeutics
Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
1 trial -
Sparsentan
Travere Therapeutics
ANCA Associated Vasculitis
1 trial
Frequently asked questions
How many clinical projects does Travere Therapeutics have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.